Acorda Therapeutics Inc (ACOR)

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the...

Acorda Therapeutics Announces Nasdaq Delisting Notification

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in...

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of...

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference...

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023...

Form 8-K - Current report

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) following a...

Form 8-K - Current report

Form 8-K - Current report

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net...

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial...

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

Up to five approvals expected in 2024 Additional filings expected in Chile in late 2023 and in Mexico and Brazil in 2024 Acorda Therapeutics...

Form 8-K - Current report

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

INBRIJA® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million...

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand...